Tarenflurbil

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTarenflurbil
Drug Alias Name他仑氟比Flurizan他氟比尔tarenflurbilumtarenflurbil +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsAlzheimer DiseaseDementiaProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLoma Linda UniversityEncorepharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFraunhofer Institute For Molecular Biology And Applied EcologyMyrexis Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseDementiaProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG